↓ Skip to main content
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (87th percentile)
  • High Attention Score compared to outputs of the same age and source (85th percentile)

Mentioned by

policy
3 policy sources
twitter
2 X users

Readers on

mendeley
67 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Article details
Title
Economic impact of psychiatric relapse and recidivism among adults with schizophrenia recently released from incarceration: a Markov model analysis
Published in
Journal of Medical Economics, November 2014
DOI 10.3111/13696998.2014.971161
Pubmed ID
Authors
Abstract

Abstract Objectives: To develop an economic model that estimates the cost burden of psychiatric relapse and recidivism among patients with schizophrenia recently released from incarceration from a US state government perspective. Methods: A Markov state-transition model was developed to estimate the numbers of schizophrenia patients recently-released from incarceration who would experience psychiatric relapse and/or arrest and re-incarceration over a period of 3 years, along with corresponding costs. The model includes three health states: 1) in community, on therapy, 2) in community, off therapy, and 3) incarcerated. It is assumed that a patient's probability of psychiatric hospitalization increases with treatment discontinuation, and the probability of arrest increases with the occurrence of a prior psychiatric hospitalization. Data from the US Census and Bureau of Justice Statistics were used to estimate the model population. Published literature was used to estimate the risks of psychiatric relapse, arrest, and all cost inputs. State-specific incarceration rates and sentence length data (from the State of Florida) were applied. The impact on outcomes and costs was evaluated by varying the rates of antipsychotic treatment following release from incarceration and the annual risk of medication discontinuation. Results: Among 34,500 persons released from incarceration in the state of Florida annually, 5,307 were estimated to have schizophrenia. The cumulative three-year costs to the state government were $21,146,000 and $25,616,000 for criminal justice and psychiatric hospitalization costs, respectively ($3,984 per patient criminal justice; $4,827 per patient hospitalization costs). A relative 20% increase in the proportion of patients receiving antipsychotic treatment following release from incarceration decreased total cumulative costs over three years by $1,871,100 ($353 per patient). Conclusions: The economic impact of psychiatric relapse and recidivism among patients with schizophrenia is substantial from the state government perspective. This general model can be made state-specific by utilizing local criminal justice data sources.

Login to access the Attention Digest and the Sentiment Analysis related to this output.

Timeline Attention over time Attention Score history
Login to access the full charts related to this output.
X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 67 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Geographical breakdown
Country Count As %
Italy 1 1%
Unknown 66 99%

Demographic breakdown

Readers by professional status
Readers by professional status Count As %
Student > Ph. D. Student 13 19%
Researcher 9 13%
Student > Bachelor 7 10%
Other 5 7%
Student > Master 4 6%
Other 6 9%
Unknown 23 34%
Readers by discipline
Readers by discipline Count As %
Medicine and Dentistry 10 15%
Psychology 9 13%
Nursing and Health Professions 6 9%
Social Sciences 3 4%
Biochemistry, Genetics and Molecular Biology 2 3%
Other 9 13%
Unknown 28 42%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 February 2018.
All research outputs
#4,291,175
of 32,332,113 outputs
Outputs from Journal of Medical Economics
#223
of 1,779 outputs
Outputs of similar age
#50,165
of 409,764 outputs
Outputs of similar age from Journal of Medical Economics
#4
of 27 outputs
Altmetric has tracked 32,332,113 research outputs across all sources so far. Compared to these this one has done well and is in the 86th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,779 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.3. This one has done well, scoring higher than 86% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 409,764 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 87% of its contemporaries.
We're also able to compare this research output to 27 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 85% of its contemporaries.